Advancing SUMO2 therapy toward clinical application in frontotemporal dementia
Active Project Grant Awarded Last action
- Award ID
- HT9425261E385
- Recipient
-
Istituto DI Ricerche Farmacologiche Mario Negri UEI TN35LLAJBF16
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $3,499,020
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 4% complete
- Place of performance
- Italy
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded $3.499 million to Istituto DI Ricerche Farmacologiche Mario Negri on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to advance SUMO2 therapy toward clinical application in frontotemporal dementia. The project grant runs through August 31, 2030, with place of performance in Italy. The recipient is a private, independent biomedical research organization that develops new therapeutic approaches by investigating mechanisms of biological systems and pathological alterations. This award supports basic and applied research aimed at transforming health care through innovative medical solutions aligned with Defense Health Agency priorities.
Quick answers
Who received award HT9425261E385?
HT9425261E385 was awarded to Istituto DI Ricerche Farmacologiche Mario Negri by Defense Health Agency (Department of Defense) on September 1, 2026.
How much is award HT9425261E385 worth?
$3,499,020 has been obligated on HT9425261E385.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award